MannKind (MNKD) investor relations material

Company overview and recent developments

• Operates as an inhalation platform company with two FDA-approved products: inhaled insulin (Afrezza) and TYVASO DPI, plus a growing pipeline and recent acquisition in cardiometabolic space.

• Afrezza received pediatric approval last week, expanding its market potential significantly.

• Announced positive momentum in the 201 nintedanib program, with first patient dosed in phase II.

• FUROSCIX is scaling with an auto-injector, targeting hospital and nephrology segments.

• Partnership with United Therapeutics for ralinepag and ongoing development of additional dry powder inhalation products.

Afrezza pediatric launch and market opportunity

• Pediatric approval expected to drive 25%-30% market share in the segment, with every 10% share representing ~$150 million in revenue.

• Pediatric market offers a compounding effect as children transition to adult care, supporting long-term growth.

• Early launch signals strong demand, with rapid uptake among prescribers and patients.

• Commercial strategy includes a $35 co-pay program for children through year-end to address cost concerns.

• Clinical data shows Afrezza is as effective as insulin pumps, supporting its use both standalone and in combination with pumps.

Commercial infrastructure and sales strategy

• Sales force expanded from 50 to 70 reps, now covering both adult and pediatric endocrinology, plus nephrology for FUROSCIX.

• 20 key account managers focus on health systems; 70 full-time reps cover 1,500 concentrated prescribers.

• No significant further expansion planned in next 18 months; future increases tied to Type 2 market entry and high-dose cartridge launch (expected ~2028).

• Early pediatric launch has generated more prescriber requests than previous two years combined.